吲哚布芬片与拜阿司匹林片对缺血性心肌病患者尿酸及痛风的影响
Journal: Frontier Forum of Clinical Medicine DOI: 10.12238/ffcr.v3i1.12597
Abstract
目的：比较长期服用吲哚布芬片与拜阿司匹林片对缺血性心肌病患者血尿酸水平以及痛风发生率的影响。方法：选取2023年1月1日至2024年1月1日诸暨市第二人民医院内科病房收治的100例缺血性心肌病患者。根据治疗方案不同平均分为两组：吲哚布芬组和拜阿司匹林组。前者给予吲哚布芬片口服治疗,后者给予拜阿司匹林片口服治疗。比较治疗前后两组患者在一般临床资料、尿酸、肌酐、脑钠肽、痛风发生率等方面的差异。结果：两组患者在基线资料上无统计学差异。治疗6个月后,吲哚布芬组患者脑钠肽、尿酸、肌酐水平较拜阿司匹林组显著降低,吲哚布芬组患者痛风发生率较拜阿司匹林组显著降低。结论：吲哚布芬片较拜阿司匹林片可更好的控制缺血性心肌病患者的尿酸和肌酐水平,从而减少缺血性心肌病患者痛风的发生率。
Keywords
吲哚布芬片；缺血性心肌病；血尿酸；痛风
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Xu S,Liu Z,Tang M,et al.Burden, risk factors,and projec tions of ischemic heart disease in China (1990-2021): findi ngs from the 2021 GBD study[J]. Front Cardiovasc Med, 2025,12:1549147.
[2] Park S, Chi S, Yang JH, et al. Comparison of uric acid elevation between aspirin-ticagrelor and aspirin-clopidogr el during dual antiplatelet therapy[J]. Int J Clin Pharmacol Ther,2024,62(11):534-7.
[3] Lou X, Jin J, Gong J, et al. Comparison of the Effects of Indobufen and Warfarin in a Rat Model of Adenine-Induced Chronic Kidney Disease[J].Med Sci Monit,2019,25:3566-72.
[4] Cavalcante DVS, Krishna MM, Joseph M, et al. Indobufen versus aspirin in patients with indication for antiplatelet therapy: A systematic review and meta-analysis[J]. Vascul Pharmacol,2025,158:107465.
[5] Del Buono MG, Moroni F, Montone RA, et al. Ischemic Cardiomyopathy and Heart Failure After Acute Myocardial Infarction[J].Curr Cardiol Rep, 2022,24(10):1505-15.
[6] Cosemans JM, Angelillo-Scherrer A, Mattheij NJ, et al. The effects of arterial flow on platelet activation, thrombus growth,and stabilization[J]. Cardiovasc Res, 2013,99(2):342-52.
[7] Hybiak J, Broniarek I, Kiryczynski G, et al. Aspirin and its pleiotropic application[J].Eur J Pharmacol, 2020,866:1727 62.
[8] Louthrenoo W, Kasitanon N, Wichainun R, et al. Effect of minidose aspirin on renal function and renal uric acid handling inhealthy young adults[J].J Clin Rheumatol,2002,8(6):299-304.
[9] Zhang Y, Neogi T, Chen C, et al. Low-dose aspirin use and recurrent gout attacks[J].Ann Rheum Dis, 2014,73(2):385-90.
[10] Bhana N, McClellan KJ. Indobufen: an updated review of its use in the management of atherothrombosis[J]. Drugs Aging,2001,18(5):369-88.
[11] Yang M, Ye Z, Mei L, et al. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronar yatherosclerosis[J].Eur J Clin Pharmacol, 2021,77(12):1815-23.
[2] Park S, Chi S, Yang JH, et al. Comparison of uric acid elevation between aspirin-ticagrelor and aspirin-clopidogr el during dual antiplatelet therapy[J]. Int J Clin Pharmacol Ther,2024,62(11):534-7.
[3] Lou X, Jin J, Gong J, et al. Comparison of the Effects of Indobufen and Warfarin in a Rat Model of Adenine-Induced Chronic Kidney Disease[J].Med Sci Monit,2019,25:3566-72.
[4] Cavalcante DVS, Krishna MM, Joseph M, et al. Indobufen versus aspirin in patients with indication for antiplatelet therapy: A systematic review and meta-analysis[J]. Vascul Pharmacol,2025,158:107465.
[5] Del Buono MG, Moroni F, Montone RA, et al. Ischemic Cardiomyopathy and Heart Failure After Acute Myocardial Infarction[J].Curr Cardiol Rep, 2022,24(10):1505-15.
[6] Cosemans JM, Angelillo-Scherrer A, Mattheij NJ, et al. The effects of arterial flow on platelet activation, thrombus growth,and stabilization[J]. Cardiovasc Res, 2013,99(2):342-52.
[7] Hybiak J, Broniarek I, Kiryczynski G, et al. Aspirin and its pleiotropic application[J].Eur J Pharmacol, 2020,866:1727 62.
[8] Louthrenoo W, Kasitanon N, Wichainun R, et al. Effect of minidose aspirin on renal function and renal uric acid handling inhealthy young adults[J].J Clin Rheumatol,2002,8(6):299-304.
[9] Zhang Y, Neogi T, Chen C, et al. Low-dose aspirin use and recurrent gout attacks[J].Ann Rheum Dis, 2014,73(2):385-90.
[10] Bhana N, McClellan KJ. Indobufen: an updated review of its use in the management of atherothrombosis[J]. Drugs Aging,2001,18(5):369-88.
[11] Yang M, Ye Z, Mei L, et al. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronar yatherosclerosis[J].Eur J Clin Pharmacol, 2021,77(12):1815-23.
Copyright © 2025 何国栋, 宣林峰, 朱乐乐
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
